Collectively, our study demonstrated that SASP-related p16/IL6 axis is responsible for sorafenib resistance, providing a new strategy for HCC patients to overcome the acquisition of sorafenib resistance. The gene discussed is CDKN2A; the disease is hepatocellular carcinoma.